Preclinical Phase 1 Phase 2 Phase 3
    AEZS-120 and Erk inhibitor available for out-licensing




















Zoptarelin Doxorubicin:
Rights out-licensed to
Synopharm A-Think
for China, Hong Kong and Macau for endometrial cancer indication

Oncology Oncology Endocrine Therapy Endocrine Therapy